Aroa Biosurgery Limited (AROAF)
| Market Cap | 167.81M +72.4% |
| Revenue (ttm) | 59.34M +22.6% |
| Net Income | 2.67M |
| EPS | 0.01 |
| Shares Out | n/a |
| PE Ratio | 62.78 |
| Forward PE | 54.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.5200 |
| Previous Close | 0.5200 |
| Day's Range | 0.5200 - 0.5200 |
| 52-Week Range | 0.3845 - 0.5220 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About Aroa Biosurgery
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de... [Read more]
News
Aroa Biosurgery Earnings Call Transcript: H2 2026
Revenue grew 23% to NZD 104 million, driven by Myriad's 54% growth and high margins. Profitability and strong cash flow were achieved, with significant investments planned for sales expansion and Symphony's market opportunity. FY 2027 guidance targets 13%–23% revenue growth.
Aroa Biosurgery Annual report: H2 2026
Aroa Biosurgery has published its H2 2026 annual report on May 25, 2026.
Aroa Biosurgery Slides: H2 2026
Aroa Biosurgery has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 25, 2026.
Aroa Biosurgery Earnings Call Transcript: Q3 2026
Clinical and commercial momentum is strong, with Myriad outperforming in trauma and Symphony poised to benefit from US reimbursement changes. FY26 revenue and EBITDA are tracking toward the upper end of guidance, with ongoing profitability and positive cash flow.
Aroa Biosurgery Earnings release: Q3 2026
Aroa Biosurgery released its Q3 2026 earnings on February 2, 2026, summarizing the period's financial results.
Aroa Biosurgery Slides: Q3 2026
Aroa Biosurgery has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 2, 2026.
Aroa Biosurgery Earnings Call Transcript: H1 2026
Revenue grew 13% YoY to $44.9M with positive EBITDA and strong cash flow. Myriad sales surged 33%, and Tela Bio expanded its commercial team and product pipeline. CMS reimbursement changes may disrupt competitors, creating new opportunities.
Aroa Biosurgery Quarterly report: H1 2026
Aroa Biosurgery has published its H1 2026 quarterly earnings report on November 24, 2025.
Aroa Biosurgery Slides: H1 2026
Aroa Biosurgery has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 24, 2025.
Aroa Biosurgery Earnings Call Transcript: Q2 2026
Achieved a fourth consecutive quarter of positive cash flow, with record Myriad sales up over 30% year-over-year and strong cash reserves. Guidance for revenue and EBITDA was reiterated, while U.S. reimbursement changes and tariffs present manageable risks.
Aroa Biosurgery Earnings release: Q2 2026
Aroa Biosurgery released its Q2 2026 earnings on October 15, 2025, summarizing the period's financial results.
Aroa Biosurgery Slides: Q2 2026
Aroa Biosurgery has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 15, 2025.
Aroa Biosurgery Transcript: AGM 2025
The meeting reviewed strong 23% growth, margin improvements, and positive cash flow, with continued investment in product development and international expansion. No dividend is planned as focus remains on reinvestment. Key risks include U.S. tariffs and TELA Bio's performance.
Aroa Biosurgery Slides: FY 2025
Aroa Biosurgery has posted slides in relation to its FY 2025 quarterly earnings report, which was published on August 19, 2025.
Aroa Biosurgery Earnings Call Transcript: Q1 2026
Sales and cash flow tracked in line with expectations, with strong Myriad and TELA Bio performance. Guidance for revenue and EBITDA was reaffirmed, and CMS reimbursement proposals could benefit Symphony if enacted.
Aroa Biosurgery Earnings release: Q1 2026
Aroa Biosurgery released its Q1 2026 earnings on July 28, 2025, summarizing the period's financial results.
Aroa Biosurgery Slides: Q1 2026
Aroa Biosurgery has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 28, 2025.
Aroa Biosurgery Earnings Call Transcript: H2 2025
Revenue grew 23% to AUD 84.7 million, with first positive normalized EBITDA of AUD 4.2 million and strong cash position. Myriad drove growth, while guidance for FY 2026 targets 10–20% revenue increase and continued profitability.
Aroa Biosurgery Annual report: H2 2025
Aroa Biosurgery has published its H2 2025 annual report on June 26, 2025.
Aroa Biosurgery Slides: H2 2025
Aroa Biosurgery has posted slides in relation to its H2 2025 quarterly earnings report, which was published on June 26, 2025.